BRAF, NRAS, HRAS genes profile in human melanoma cell lines;Geny BRAF, NRAS, HRAS w liniach komórkowych czerniaka ludzkiego

Przeglad Dermatologiczny

Volumn 96, Issue 4, 2009, Pages 265-270

  Czajkowski, Rafał ^a,b   Placek, Waldemar ^b   Tadrowski, Tadeusz ^b   Pokrywczyńska, Marta ^b   Zegarska, Barbara ^a,b   Drewa, Tomasz ^b  

^a Wojewódzka Przychodnia Dermatologiczna W Bydgoszczy ^*  (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

BRAF; Melanoma; Pathogenesis; RAS

Indexed keywords

B RAF KINASE;

ARTICLE; CANCER CELL CULTURE; CELL LINE; CONTROL GROUP; EXON; GENE MUTATION; HUMAN; LEUKOCYTE; MELANOMA CELL; MOLECULAR BIOLOGY; POLYMERASE CHAIN REACTION;

EID: 70349575474     PISSN: 00332526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Negrier S., Fervers B., Bailly C., Beckendorf V., Cupissol D., Dalac S. i inni: Cutaneous melanoma. Br J Cancer 2001, 84 (Supl. 2), 81-85.
2. Gilchrest B.A., Eller M.S., Geller A.C., Yaar M.: The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999, 340, 1341-1348. (Pubitemid 29196597)
3. Stern R.S.; PUVA follow up study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001, 44, 755-761.
4. Langärd S., Rosenberg J., Andersen A., Heldaas S.S.: Incidence of cancer among workers exposed to vinyl chloride in polyvinyl chloride manufacture. Occup Environ Med 2000, 57, 65-68. (Pubitemid 30265471)
5. Wong O., Raabe G.K.: A critical review of cancer epidemiology in the petroleum industry, with a meta-analysis of a combined database of more than 350,000 workers. Regul Toxicol Pharmacol 2000, 32, 78-98. (Pubitemid 30764603)
6. Miracco C., Palummo N., Lavergne D., Nyongo A., Tosi P., de Villiers E.M.: Malignant melanomas: search for human papillomaviruses. Arch Dermatol 2001, 137, 826-827. (Pubitemid 32577879)
7. Piepkorn M.: Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 2000, 42, 705-722.
8. Bartek J., Lukas J., Bartkova J.: Perspective: defects in cell cycle control and cancer. J Pathol 1999, 187, 95-99. (Pubitemid 29009839)
9. Aoki Y., Niihori T., Narumi Y., Kure S., Matsubara Y.: The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 2008, 29, 992-1006.
10. Haluska F., Pemberton T., Ibrahim N., Kalinsky K.: The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol 2007, 34, 546-554. (Pubitemid 350236312)
11. Haluska F.G., Tsao H., Wu H., Haluska F.S., Lazar A., Goel V.: Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006, 12, 2301s-2307s.
12. Dahl C., Guldberg P.: The genome and epigenome of malignant melanoma. APMIS 2007, 115, 1161-1176.
13. Takata M., Saida T.: Genetic alterations in melanocytic tumors. J Dermatol Sci 2006, 43, 1-10.
14. Davies H., Bignell G.R., Cox C.: Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949-954. (Pubitemid 34716871)
15. Dong J., Phelps R.G., Qiao R., Yao S., Benard O., Ronai Z. i inni: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003, 63, 3883-3885. (Pubitemid 36917898)
16. Sasaki Y., Niu C., Makino R., Kudo C., Sun C., Watanabe H. i inni: BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 2004, 123, 177-183. (Pubitemid 38833479)
17. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M. i inni: High frequency of BRAF mutations in nevi. Nat Genet 2002, 33, 19-20.
18. O'Hara B.M., Oskarsson M., Tainsky M.A., Blair D.G.: Mechanism of activation of human ras genes cloned from a gastric adenocarcinoma and a pancreatic carcinoma cell line. Cancer Res 1986, 46, 4695-4700. (Pubitemid 16000346)
19. Omholt K., Karsberg S., Platz A., Kanter L., Ringborg U., Hansson J.: Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002, 8, 3468-3474. (Pubitemid 35340723)
20. van Elsas A., Zerp S.F., van der Flier S., Krüse K.M., Aarnoudse C., Hayward N.K. i inni: Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996, 149, 883-893. (Pubitemid 26334172)
21. Raybaud F., Noguchi T., Marics I., Adelaide J., Planche J., Batoz M. i inni: Detection of a low frequency of activated ras genes in human melanomas using a tumorigenicity assay. Cancer Res 1988, 48, 950-953. (Pubitemid 18061892)
22. Van't Veer L.J., Burgering B.M., Versteeg R., Boot A.J., Ruiter D.J., Osanto S. i inni: N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989, 9, 3114-3116.
23. Albino A.P., Nanus D.M., Mentle I.R., Cordon-Cardo C., McNutt N.S., Bressler J. i inni: Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 1989, 4, 1363-1374.
24. Shukla V.K., Hughes D.C., Hughes L.E., McCormick F., Padua R.: Ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development. Oncogene Res 1989, 5, 121-127. (Pubitemid 20018406)
25. Ball N.J., Yohn J.J., Morelli J.G., Norris D.A., Golitz L.E., Hoeffler J.P.: RAS mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994, 102, 285-290. (Pubitemid 24095491)
26. Carr J., Mackie R.M.: Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 1994, 131, 72-77. (Pubitemid 24234291)
27. Platz A., Ringborg U., Månsson Brahme E., Lagerlöf B.: Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res 1994, 4, 169-177.
28. Jafari M., Papp T., Kirchner S., Diener U., Henschler D., Burg G. i inni: Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol 1995, 121, 23-30.
29. Platz A., Sevigny P., Norberg T., Ring P., Lagerlöf B., Ringborg U.: Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases. Br J Cancer 1996, 74, 936-941. (Pubitemid 26319328)
30. Jiveskog S., Ragnarsson-Olding B., Platz A., Ringborg U.: N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 1998, 111, 757-761. (Pubitemid 28509314)
31. Demunter A., Ahmadian M.R., Libbrecht L., Stas M., Baens M., Scheffzek K. i inni: A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res 2001, 61, 4916-4922. (Pubitemid 32691910)
32. Eskandarpour M., Hashemi J., Kanter L., Ringborg U., Platz A., Hansson J.: Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst 2003, 95, 790-798. (Pubitemid 36798425)
33. Demunter A., Stas M., Degreef H., De Wolf-Peeters C., van den Oord J.J.: Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 2001, 117, 1483-1489.
34. Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A., Mueller-Berghaus J. i inni: B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE 2007, 2: e236.
35. Reifenberger J., Knobbe C.B., Sterzinger A.A., Blaschke B., Schulte K.W., Ruzicka T. i inni: Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004, 109, 377-384. (Pubitemid 38252766)
36. Bauer J., Curtin J.A., Pinkel D., Bastian B.C.: Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007, 127, 179-182. (Pubitemid 46005676)
37. van Dijk M.C., Bernsen M.R., Ruiter D.J.: Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol 2005, 29, 1145-1151.
38. Tsao H., Zhang X., Fowlkes K., Haluska F.G.: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000, 60, 1800-1804. (Pubitemid 30207633)
39. Goel V.K., Lazar A.J., Warneke C.L., Redston M.S., Haluska F.G.: Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006, 126, 154-160. (Pubitemid 43336107)